World's Best Scientists 2026 revealed!
Joseph D. Rosenblatt

Joseph D. Rosenblatt

D-Index & Metrics

Biology and Biochemistry

D-Index
62
Citations
17411
World Ranking
10623
National Ranking
4616

Overview

Joseph D. Rosenblatt is affiliated with the University of Miami in the United States. Their research primarily spans the fields of Medicine and Biochemistry, Genetics and Molecular Biology, with a notable focus on Oncology, Pathology and Forensic Medicine, Molecular Biology, Immunology, and Cancer Research as subfields.

Their work covers multiple topics including Lymphoma Diagnosis and Treatment, CAR-T cell therapy research, Angiogenesis and VEGF in Cancer, Immune Cell Function and Interaction, Cancer, Hypoxia, and Metabolism, Biosimilars and Bioanalytical Methods, and Immunotherapy and Immune Responses.

Frequent collaborators in their research include Caron A. Jacobson, Alison R. Sehgal, Pashna N. Munshi, David G. Maloney, and Sven de Vos.

Joseph D. Rosenblatt has published extensively in several venues, most notably:

  • Blood (8 publications)
  • arXiv (Cornell University) (6 publications)
  • Cancer Research (5 publications)
  • Transplantation and Cellular Therapy (3 publications)
  • Cells (2 publications)

Representative recent papers authored or co-authored by Joseph D. Rosenblatt include:

  • Axicabtagene ciloleucel in relapsed or refractory indolent non-Hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial, 2021, The Lancet Oncology
  • Primary Analysis of Zuma-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL), 2020, Blood
  • Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5), 2023, Blood
  • Inhibition of Vasculogenic Mimicry and Angiogenesis by an Anti-EGFR IgG1-Human Endostatin-P125A Fusion Protein Reduces Triple Negative Breast Cancer Metastases, 2021, Cells
  • 3-Year Follow-up Analysis of ZUMA-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL), 2022, Blood

Best Publications

  • Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma

    Anas Younes;Ajay K. Gopal;Scott E. Smith;Stephen M. Ansell

  • Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study

    Barbara Pro;Ranjana Advani;Pauline Brice;Nancy L. Bartlett

  • B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose-escalation trial of rituximab

    R. John Looney;Jennifer H. Anolik;Debbie Campbell;Raymond E. Felgar

  • Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: a phase 1 clinical-laboratory correlative trial.

    Judith E. Karp;Jeffrey E. Lancet;Scott H. Kaufmann;David W. End

  • High Rate of HTLV-II Infection in Seropositive IV Drug Abusers in New Orleans

    Helen Lee;Priscilla Swanson;Vernon S. Shorty;Jerome A. Zack

  • The relationship of FcγRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus

    Jennifer H. Anolik;Debbie Campbell;Raymond E. Felgar;Faith Young

  • A phase I dose-escalation trial of 2-deoxy- d -glucose alone or combined with docetaxel in patients with advanced solid tumors

    Luis E. Raez;Kyriakos Papadopoulos;Alejandro D. Ricart;E. Gabriella Chiorean

  • Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma

    Robert Chen;Ajay K. Gopal;Scott E. Smith;Stephen M. Ansell

  • The Role of Cyclic AMP in the Chemotactic Responsiveness and Spontaneous Motility of Rabbit Peritoneal Neutrophils The Inhibition of Neutrophil Movement and the Elevation of Cyclic AMP Levels by Catecholamines, Prostaglandins, Theophylline and Cholera Toxin

    Israel Rivkin;Joseph Rosenblatt;Elmer L. Becker

  • A second isolate of HTLV-II associated with atypical hairy-cell leukemia.

    Joseph D. Rosenblatt;David W. Golde;William Wachsman;Janis V. Giorgi

  • A Phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma

    Andres Forero-Torres;John P. Leonard;Anas Younes;Joseph D. Rosenblatt

  • A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies.

    Nancy L. Bartlett;Anas Younes;Matthew H. Carabasi;Andres Forero

  • Durable remissions in a pivotal phase 2 study of brentuximab vedotin in relapsed or refractory Hodgkin lymphoma.

    Ajay K. Gopal;Robert Chen;Scott E. Smith;Stephen M. Ansell

  • Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma.

    Ranjana Advani;Andres Forero-Torres;Richard R. Furman;Joseph D. Rosenblatt

  • B cell regulation of the anti-tumor response and role in carcinogenesis

    Marc Schwartz;Yu Zhang;Joseph D. Rosenblatt

  • Increased rejection of primary tumors in mice lacking B cells: Inhibition of anti‐tumor CTL and TH1 cytokine responses by B cells

    Sangeeta Shah;Anagha A. Divekar;Shannon P. Hilchey;Hyun Mi Cho

  • A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies

    Michelle A. Fanale;Andres Forero-Torres;Joseph D. Rosenblatt;Ranjana H. Advani

  • Identification of the gene responsible for human T-cell leukaemia virus transcriptional regulation

    Alan J. Cann;Joseph D. Rosenblatt;William Wachsman;Neil P. Shah

  • The x gene is essential for HTLV replication.

    Irvin S. Y. Chen;Dennis J. Slamon;Joseph D. Rosenblatt;Neil P. Shah

  • Efficient and sustained gene expression in primary T lymphocytes and primary and cultured tumor cells mediated by adeno-associated virus plasmid DNA complexed to cationic liposomes.

    Ramila Philip;Elisa Brunette;Lydia Kilinski;Deepa Murugesh

Frequent Co-Authors

Nancy L. Bartlett
Nancy L. Bartlett Washington University in St. Louis
Irvin S. Y. Chen
Irvin S. Y. Chen University of California, Los Angeles
Howard J. Federoff
Howard J. Federoff University of California, Irvine
Ranjana H. Advani
Ranjana H. Advani Stanford University
Eckhard R. Podack
Eckhard R. Podack University of Miami
Joseph M. Connors
Joseph M. Connors University of British Columbia
Anas Younes
Anas Younes AstraZeneca (United Kingdom)
Vicente Planelles
Vicente Planelles University of Utah
William J. Bowers
William J. Bowers University of Rochester
Andreas Engert
Andreas Engert University of Cologne

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

There are many accessible pathways for students pursuing careers in biology, biochemistry, and related fields. For those seeking fast-track options, accelerated biology degree programs offer the opportunity to complete coursework more quickly, allowing graduates to enter the workforce or move on to advanced studies sooner.

Healthcare careers are also highly popular, with programs like online asn programs providing foundational training for aspiring nurses. These programs are designed to offer flexibility and prepare students to sit for the NCLEX-RN exam.

Another growing area is nutrition science, where students can gain expertise in food, health, and wellness through the best online nutrition degree options. These degrees can open doors to roles in research, clinical settings, or community health.

For those interested in healthcare leadership, cahme accredited online mha programs deliver essential managerial and organizational skills, helping graduates advance into high-demand healthcare administration positions.

Best Scientists Citing Joseph D. Rosenblatt

Trending Scientists